- Home
- AVBH vs GALT Comparison
AVBH vs GALT Comparison
Compare AVBH & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.47
Company Overview
Basic Information| Metric | AVBH | GALT |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | 151 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.3M | 297.0M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | AVBH | GALT |
|---|---|---|
| Price | $31.86 | $3.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $35.33 | $8.50 |
| AVG Volume (30 Days) | 173.8K | ★ 1.0M |
| Earning Date | 04-27-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $350.70 | N/A |
| Revenue Next Year | $11.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.95 | $2.03 |
| 52 Week High | $34.18 | $7.13 |
Technical Indicators
Market Signals| Indicator | AVBH | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 45.02 |
| Support Level | $31.67 | $2.30 |
| Resistance Level | $32.98 | $4.35 |
| Average True Range (ATR) | 0.93 | 0.49 |
| MACD | -0.14 | -0.18 |
| Stochastic Oscillator | 47.41 | 9.01 |
Price Performance
Historical Comparison AVBH
GALT
About AVBH Avidbank Holdings Inc.
Avidbank Holdings Inc is a full-service commercial bank. It offers various services such as commercial and industrial lending, venture lending, structured finance, asset-based lending, sponsor finance, real estate construction, and commercial real estate lending.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.